Paradigm Health
-78%
est. 2Y upside i
Paradigm Health is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers.
Rank
#4201
Sector
Healthcare Technology Systems
Est. Liquidity
~4Y
Data Quality
Data: MediumParadigm Health operates in a high-growth sector (AI in clinical trials) with a strong competitive moat and impressive customer traction (15 of top 20 pharma companies).
Last updated: March 10, 2026
Paradigm Health successfully leverages its proprietary AI platform and integrated oncology network to accelerate growth to 30% YoY, expanding its market penetration and fending off incumbent threats. This drives revenue to ~$16.9M by 2027 and justifies a 50x revenue multiple, leading to an $845M valuation, allowing for meaningful returns after investor preferences.
The company maintains its current 17% YoY growth, reaching ~$13.7M in revenue by 2027. However, the high initial valuation and competitive pressures lead to a multiple compression to 30x revenue, resulting in a $411M valuation, which provides minimal to no return for common stock after accounting for liquidation preferences.
Dominant incumbents like Epic and CVS Health aggressively enter the clinical trials space, eroding Paradigm Health's market share and compressing its valuation multiple to 10x revenue. Growth stalls, leading to a ~$137M valuation by 2027, which is significantly below the $281M in liquidation preferences, effectively wiping out common stock value.
Preference Stack Risk
severeFunding Intensity
63%Investors hold $281M in liquidation preferences ahead of common stock, representing 63.4% of the current $443M valuation.
Dilution Risk
highAs a Series B company with significant prior funding, further dilution from future funding rounds is likely before a liquidity event.
Secondary Liquidity
limitedSecondary market liquidity is likely limited for a Series B company, with potential for opportunistic tender offers but no active public market.
Questions to Ask at the Interview
Strategic questions based on Paradigm Health's data — designed to show you've done your homework.
- 1
“Given the strong competitive moat from your AI platform and oncology network, how do you plan to specifically counter the significant threat posed by established players like Epic, CVS, and Walgreens entering the clinical trials space?”
- 2
“With current revenue around $10M and a weighted growth rate of 17% YoY, what are the key strategic initiatives to accelerate growth significantly over the next two years to justify the current valuation and achieve a successful exit?”
- 3
“Considering the $281M in total funding relative to the $443M valuation, how is Paradigm Health thinking about a liquidity event timeline and ensuring meaningful returns for common stock holders, especially given the potential for liquidation preferences?”
Community
Valuation Sentiment
Our model estimates -78% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.